May 25, 2012 08:30 AM Eastern Daylight TimeLOS ANGELES--(BUSINESS
WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”)
(OTCBB: IMUC), a biotechnology company focused on the development of novel
immune-based cancer therapies, announced today that its common stock has been
approved for listing on the NYSE: MKT. Trading is expected to commence on the
NYSE: MKT on Wednesday, May 30th, 2012 under the ticker symbol ‘IMUC’. THE
NYSE: AMEX changed its name to NYSE: MKT earlier this month. “This listing marks an
important step in our Company’s development by giving us access to a broader
investor base and should provide increased transparency and liquidity for
investors owning our stock.” . “We are
pleased to begin trading on NYSE MKT,” said Manish Singh, Ph.D., President and
CEO of ImmunoCellular Therapeutics. “This listing marks an important step in
our Company’s development by giving us access to a broader investor base and should
provide increased transparency and liquidity for investors owning our stock.”“We welcome ImmunoCellular
to the NYSE MKT family of listed companies,” said Scott Cutler, EVP and Co-Head
of U.S. Listings and Cash Execution at NYSE Euronext. “IMUC will be joining
other growth oriented companies in the U.S.
About ImmunoCellular Therapeutics, Ltd.ImmunoCellular
Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is
developing immune-based therapies for the treatment of brain and other cancers.
The Company has commenced a Phase II trial of its lead product candidate,
ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated
antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.
Posts
No comments:
Post a Comment